Premium
Aspirin 300 mg/day is effective for treating aspirin‐exacerbated respiratory disease
Author(s) -
Comert S.,
Celebioglu E.,
Yucel T.,
Erdogan T.,
Karakaya G.,
Onerci M.,
Kalyoncu A. F.
Publication year - 2013
Publication title -
allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.363
H-Index - 173
eISSN - 1398-9995
pISSN - 0105-4538
DOI - 10.1111/all.12269
Subject(s) - medicine , interquartile range , aspirin , asthma , respiratory disease , gastroenterology , sinusitis , surgery , lung
Abstract Background Aspirin desensitization ( AD ) treatment at doses of up to 1300 mg/day improves outcomes in aspirin‐exacerbated respiratory disease ( AERD ). The aim of this study was to investigate the efficacy of aspirin 300 mg/day in the treatment of patients with AERD . Methods The study included 40 patients diagnosed in our clinic as AERD that were desensitized and treated with aspirin 300 mg/day between D ecember 2005 and D ecember 2012. Changes from the baseline status were analyzed at 1 year and at 3 years of follow‐up. Results Of the 40 patients included, 24 (60%) were female and median (interquartile range [ IQR ]) age was 45 (40–51) years. Median ( IQR ) duration of AD was 31.5 (10.5–48.5) months. In total, 29 patients continued treatment for at least 1 year and 18 patients for at least 3 years. The annual rate of use of systemic corticosteroid regimens, episodes of sinusitis, and surgery was significantly lower both at 1 year ( P = 0.002, P = 0.01, and P < 0.001, respectively) and at 3 years ( P = 0.001, P = 0.03, and P = 0.002, respectively). Significant improvement was observed in the nasal congestion score ( P = 0.01) and sense of smell score ( P = 0.05) at 1 year and in the postnasal drainage score ( P = 0.01) at 3 years. Conclusion Daily treatment with aspirin 300 mg had beneficial effects in patients with AERD , especially for the control of upper airway disease.